Inclusion Criteria:

          -  A histologically or pathologically confirmed diagnosis of AML based on 2016 WHO
             classification. Patients with Complex Karyotype AML (CK-AML) and TP53-mutated AML are
             eligible for this study.

          -  AML has relapsed after or is refractory to, first-line therapy, with a maximum of
             three prior lines of therapy. Patients whose AML has FLT3 or IDH1/IDH2 mutations
             should have received at least one available FLT3 or IDH1/IDH2 inhibitors

          -  Age 18 years and older

          -  ECOG performance status ≤ 2

          -  Patients who have undergone allo-HSCT are eligible if they are ≥ 30 days post stem
             cell infusion, have no evidence of graft versus hose disease ( GVHD ) > Grade 1, and
             are ≥ 10 days off all immunosuppressive therapy

          -  Previous cytotoxic chemotherapy must have been completed at least 10 days prior to day
             1 of treatment on the study and all AEs (excluding alopecia, acne, rash) due to agents
             administered earlier should have recovered to < Grade 1. Patients with hematologic
             malignancies are expected to have hematologic abnormalities at study entry. These
             abnormalities which are thought to be primarily related to the underlying leukemia,
             are not considered to be toxicities (AE) and do not need to resolve to < Grade 1

          -  All biologic agents including hematopoietic growth factors must have been stopped at
             least 1 week prior to day 1 of treatment on the study

          -  Patients must have adequate organ function as defined below:

               -  Direct bilirubin ≤2X the institutional upper limit of normal (ULN) (except in
                  patients with leukemic infiltration of the liver)

               -  AST(SGOT)/ALT(SGPT) ≤3X ULN (except if attributable to leukemic infiltration of
                  the liver)

               -  Alkaline phosphatase ≤5X ULN

               -  Creatinine Clearance (CrCl) ≥ 45 mL/min (except in patients with evidence of
                  tumor lysis syndrome)

               -  Patients with a history of CNS leukemia must be stable with clear CSF for > 2
                  months prior to day 1 of treatment (patient can receive intrathecal maintenance
                  chemotherapy)

          -  Female patients of childbearing potential must have a negative pregnancy test <1 week
             prior to enrollment. Female patients of childbearing potential who are sexually active
             and male patients who are sexually active and have female partners of childbearing
             potential must agree to use highly effective method of contraception with their
             partners during exposure to study drugs and for 30 days after the last dose of study
             drugs.

          -  Ability to understand and willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Patients receiving any other investigational agents, or concurrent chemotherapy or
             immunotherapy

          -  Patients with acute promyelocytic leukemia (APL) confirmed with t(15;17) (i.e. FAB
             subtype M3 and M3 variant)

          -  Prior treatment with any asparaginase product. Patients who received ≤12 weeks of a
             BCL-2 inhibitor including venetoclax are eligible.

          -  Absolute peripheral blast > 100,000/μL. Hydroxyurea for blast count control is
             permitted before starting treatment and up to maximum of 10 days after starting
             treatment on the study. The decision to start hydroxyurea during this time is at the
             discretion of the treating physician.

          -  Patients with the following clinical histories are excluded:

               -  severe pancreatitis not related to cholelithiasis. Severe acute pancreatitis is
                  defined by lipase elevation >5X ULN and with signs or symptoms

               -  unprovoked deep venous thrombosis (DVT)

               -  pulmonary emboli

               -  hemorrhagic or thromboembolic stroke

               -  other malignancies requiring systemic chemotherapy, immunotherapy or targeted
                  therapy in the last three months

          -  Active, uncontrolled infection; patients with infection under active treatment and
             controlled with antibiotics are eligible

          -  Uncontrolled intercurrent illness including, but not limited to, symptomatic
             congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric
             illness/social situations that per site Principal Investigator's judgment would limit
             compliance with study requirements

          -  Pregnant women and female patients who are lactating and do not agree to stop breast-
             feeding.

          -  Uncontrolled active seizure

          -  Any other clinical conditions that in the opinion of the investigator would make the
             subject unsuitable for the study